The subscription period for Dicot's rights issue begins today on October 12, 2021

Press release: Uppsala, October 12, 2021. Today on October 12, 2021, the subscription period for the rights issue in Dicot AB (publ) ("Dicot" or the "Company"), which was made public on September 8, 2021 and resolved by the extra general meeting on October 6, 2021 (the "Rights Issue") commences.

The subscription period for the Rights Issue will be from October 12, 2021 until October 27, 2021.

Please note, however, that nominees may have a deadline for subscribing to the Rights Issue that occurs before October 27, 2021.

Summary of the Rights Issue

Subscription period: October 12, 2021 - October 27, 2021

Trading with unit rights: October 12, 2021 - October 22, 2021

Preference: For each one (1), on the record date October 8, 2021, held share, one (1) unit right was received. Five (5) unit rights entitle to subscription for one (1) unit.

Unit: One (1) unit contains three (3) newly issued shares and three (3) warrants of series 2021/2022.

Subscription price: The subscription price is 1.95 SEK per unit, corresponding to 0.65 SEK per share. The warrants are obtained free of charge.

Issue payment: Upon full subscription of the Rights Issue, the Company will receive approximately SEK 25.3 million before issue costs. In the event of full subscription of the Rights Issue and full exercise of warrants of series 2021/2022, the Company may be provided with an additional amount of approximately SEK 58.3 million before issue costs.

Subscription undertakings and guarantees: The Rights Issue is partially secured through subscription undertakings of approximately 6,2 percent and through underwriting commitments of approximately 73,8 percent. In total, 80 percent of the Rights Issue is secured by subscription undertakings and underwriting commitments.

Subscription with preemption rights

The shareholders or representatives for such shareholders who are registered in the share register kept by Euroclear Sweden AB as of the record date on October 8, 2021 will receive a pre-printed issue report with attached payment notice from Euroclear.

In the event that a different number of unit rights than those stated in the pre-printed issue report are exercised for subscription, the special application form available on the Hagberg & Aneborn AB's website www.hagberganeborn.se shall be used as a basis for subscription by cash payment.

Shareholders whose holdings of shares in the Company were nominee-registered with a bank or other nominee on the record date will not receive an issue report nor a special application form from Euroclear. Subscription and payment shall in such case instead take place in accordance with instructions from the respective nominee.

Subscription without preemption rights

Notification of subscription without preemption rights through a nominee shall be made in accordance with the instructions from the respective nominee. For subscription through an endowment insurance or an investment savings account, please contact your nominee. Notification of subscription without preemption rights is otherwise made by submitting a registration form by post or e-mail to Hagberg & Aneborn Fondkommission AB. The registration form shall be submitted to Hagberg & Aneborn no later than 15.00 on October 27, 2021. The registration form is available on the Company's website www.dicot.se and Hagberg & Aneborn Fondkommission AB's website www.hagberganeborn.se.

More information regarding the Rights Issue is available at the Company's website, www.dicot.se, Stockholm Corporate Finance AB's website, www.stockholmcorp.se and Hagberg & Aneborn Fondkommission AB's website www.hagberganeborn.se.  

Advisors

Stockholm Corporate Finance AB is acting as financial adviser to the Company in the Rights Issue. Advokatfirman Lindahl KB is acting as the legal adviser to the Company. Hagberg & Aneborn Fondkommission AB is the issuing agent in the Rights Issue.

For further information, please contact:
Göran Beijer CEO
Tel: +46 706 63 60 09
Email: [email protected]

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 2,250 shareholders. For more information, please visit www.dicot.se.

Important information

This press release is not an offer to subscribe for shares or units in Dicot and investors should not subscribe or acquire any securities. Invitation to concerned persons to subscribe for shares in Dicot will only be made through the EU growth prospectus that Dicot has published on its website on October 8, 2021.

This press release shall not, directly or indirectly, be released, published or distributed in or to the United States, Australia Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action as a whole or in part is subject to legal restrictions. Neither unit rights, units subscribed for ("BTU") or newly issued units have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTA or newly issued shares have been registered or will be registered under the United States Securities Act of 1933, as applicable, or in accordance with applicable laws in the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or in any other country where the Rights Issue or distribution of the press release is in violation of applicable laws or regulations or presupposes that a further prospectus is established, registered or that any other measure is undertaken beyond that required by Swedish law. The press release, as well as the prospectus, the application form and other documents attributable to the Rights Issue, may consequently not be distributed to any such jurisdiction.

There is no intention to register any portion of the offer in the United States and the securities issued in the Rights Issue will not be offered to the public in the United States.

The Company has not authorized any offer to the public with regards to the shares or rights that are referred to in this communication in any member state of the European Economic Area (''EEA'') besides Sweden. This communication is only addressed to and is only directed at qualified investors in other members states within the EEA.

This press release may contain certain forward-looking information that reflects Dicot's current views on future events as well as financial and operational development. Words that are "intended", "come", "judged", "expected", "can", "plan", "appreciate" and other expressions that imply indications or predictions about future developments or trends, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties because it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future performance or development and actual outcomes may differ substantially from what is stated in forward-looking information. This information, the opinions and the forward-looking statements contained in this press release are valid only on this date and may be amended without notice. Dicot makes no representations about publishing updates or revisions of forward-looking information, future events or similar circumstances other than the applicable law.

Dicots studieresultat presenteras på ledande vetenskaplig kongress

Pressmeddelande: Uppsala, 6 december 2021. Läkemedelsföretaget Dicot meddelar att resultaten som visar effekten av Dicots läkemedelskandidat kommer att presenteras på European Society for Sexual Medicine's (ESSM) årliga kongress i Rotterdam i februari 2022.


Dicot's study results to be presented at leading scientific congress

Press release: Uppsala, December 6, 2021. The pharmaceutical company Dicot announces that the results of Dicot's drug candidate will be presented at the European Society for Sexual Medicine's (ESSM) annual congress in Rotterdam in February 2022.


Dicots potensläkemedelskandidat visar effekt och lång duration även vid låg dosering

Pressmeddelande: Uppsala, 2 december 2021. Dicots senaste djurstudie visar att läkemedelskandidaten LIB-01 har effekt även vid en låg dos samt att 7 dagars duration av effekt på erektil funktion har konfirmerats. Det ger goda förutsättningar inför kommande kliniska studier på människa.


Dicot's potency drug candidate demonstrates efficiency and long duration even at a low dose

Press release: Uppsala, December 2, 2021. Dicot's latest animal study demonstrates effect of the drug candidate LIB-01 even at low dose and the 7-day duration of effect on erectile function was confirmed, which provides solid ground for coming clinical studies in humans.


Information om valberedning i Dicot AB

Uppsala, 22 november 2021. Enligt det beslut om valberedningen som fattades vid årsstämman i Dicot AB den 25 maj 2021 ska valberedningen inför årsstämman den 24 maj 2022 bestå av tre ledamöter representerande de tre största aktieägarna per den sista september 2021. För det fall någon av de tre största aktieägarna inte önskar utse en ledamot av valberedningen ska den fjärde största aktieägaren tillfrågas (och så vidare) intill dess att valberedningen består av tre ledamöter.


Dicots företrädesemission är registrerad - omvandling av BTU till aktier och teckningsoptioner samt upptagande till handel av teckningsoptioner

Uppsala, 22 november 2021. Dicot AB (publ) ("Dicot" eller "Bolaget") har genomfört en företrädesemission av units om cirka 25,3 MSEK, som avslutades den 27 oktober 2021 ("Företrädesemissionen"). Företrädesemissionen tecknades till totalt 97,9 procent. Genom Företrädesemissionen tillförs Bolaget cirka 24,7 MSEK före emissionskostnader.


Dicot's rights issue is registered - paid subscription units (BTU) are converted to shares and warrants, and trading of warrants commences

Uppsala, November 22, 2021. Dicot AB (publ) ("Dicot" or the "Company") has carried out a rights issue of units to an amount of approximately MSEK 25.3 ("the Rights Issue"). The Rights Issue was completed on October 27, 2021. The Rights Issue was subscribed to 97.9 percent. Through the Rights Issue, the Company obtains approximately MSEK 24.7 before issue costs.


Dicot AB Delårsrapport januari - september 2021

Pressmeddelande: Uppsala, 18 november 2021. Dicot ABs (publ) delårsrapport för januari - september 2021 finns nu tillgänglig på bolagets hemsida www.dicot.se.


Summary of Interim Report January - September 2021, Dicot AB

Press release: Uppsala, November 18, 2021. A summary of the Interim report January - September 2021, for Dicot AB (publ) is now available on the company website www.dicot.se 


Dicots företrädesemission tecknades till cirka 98 procent

Uppsala, 1 november 2021. Företrädesemissionen om 25,3 MSEK som offentliggjordes den 8 september 2021 och som godkändes av extra bolagsstämman den 6 oktober 2021 ("Företrädesemissionen") i Dicot AB (publ) ("Dicot" eller "Bolaget") blev nästan fulltecknad. Företrädesemissionen tecknades till totalt 97,9 procent. Genom Företrädesemissionen tillförs Bolaget cirka 24,7 MSEK före emissionskostnader.


Dicot's rights issue is subscribed with approx. 98 percent

Uppsala, November 1, 2021. The rights issue of SEK 25.3 million which was disclosed on September 8, 2021 and resolved by the extra general meeting on October 6, 2021 (the "Rights Issue")  in Dicot AB (publ) ("Dicot" or the "Company") has almost been fully subscribed. The Rights Issue was subscribed to 97.9percent. Through the Rights Issue, the Company obtains approximately SEK 24.7 million before issue costs.


Med anledning av positiva studieresultat offentliggör Dicot tilläggsprospekt

Pressmeddelande: Uppsala, 20 oktober 2021. Med anledning av att Dicot AB ("Dicot" eller "Bolaget") den 14 oktober 2021 offentliggjorde positiva resultat från en avslutad studie under den pågående teckningsperioden i Bolagets förestående företrädesemissionen av units har Bolaget nu upprättat ett tilläggsprospekt ("Tilläggsprospektet") till det EU-tillväxtprospekt som godkändes och registrerades av Finansinspektionen den 8 oktober 2021 ("Prospektet"). Tilläggsprospektet - som godkändes av Finansinspektionen idag den 20 oktober 2021 - är en del av och ska läsas tillsammans med Prospektet.


Due to positive study results Dicot publishes a supplement prospectus

Press release: Uppsala, October 20, 2021. On October 14, 2021 Dicot AB ("Dicot" or the "Company") published positive results from a completed study. Since that publication was made during the subscription period in the ongoing unit rights issue the Company has now established a supplement prospectus (the "Supplement") to the EU growth prospectus related to the invitation to subscribe for units in Dicot with preferential rights which was approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) (''SFSA'') on October 8, 2021 (hereinafter, the "Prospectus"). The Supplement - which was approved by the Swedish Financial Supervisory Authority today October 20, 2021 - forms a part of the Prospectus and shall in all respects be read together with the Prospectus.



Studie av djur med diabetes visar på effekt hos Dicots läkemedelskandidat

Pressmeddelande: Uppsala, 14 oktober 2021. Potensläkemedelsutvecklaren Dicot har precis avslutat en studie på råttor med diabetes och bevisad erektil dysfunktion. Bolagets läkemedelskandidat demonstrerade signifikant förbättrad erektion jämfört med kontrollgruppen.


Study of animals with diabetes shows effect in Dicot's drug candidate

Press release: Uppsala, October 14, 2021. Potency drug developer Dicot has just completed a study on rats with diabetes and proven erectile dysfunction. The company's drug candidate demonstrated significantly improved erections compared to vehicle.



Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted